LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Search

Moderna Inc

Abierto

Sector Salud

69.54 1.91

Resumen

Variación precio

24h

Actual

Mínimo

67.94

Máximo

70.55

Métricas clave

By Trading Economics

Ingresos

-104M

-1.3B

Ventas

-167B

241M

P/B

Media del Sector

35.86

103.001

BPA

-3.33

Margen de beneficio

-530.705

Empleados

5,600

EBITDA

-109M

-1.2B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+54.51 upside

Dividendos

By Dow Jones

Próximas Ganancias

31 oct 2024

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-65M

30B

Apertura anterior

67.63

Cierre anterior

69.54

Noticias sobre sentimiento de mercado

By Acuity

59%

41%

284 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Moderna Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 dic 2023, 13:16 UTC

Principales Movimientos del Mercado

Moderna Shares, Other Covid Vaccine Makers Hit by Warning From Pfizer

14 oct 2023, 00:02 UTC

Acciones populares

Stocks to Watch: Pfizer, Moderna, Lululemon Athletica

15 sept 2024, 07:00 UTC

Principales Noticias

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

12 sept 2024, 15:02 UTC

Principales Noticias

Moderna Cost Cuts Fail to Restore Investor Trust -- Heard on the Street -- WSJ

12 sept 2024, 10:00 UTC

Principales Noticias

Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com

6 sept 2024, 11:00 UTC

Principales Noticias

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

3 sept 2024, 04:00 UTC

Principales Noticias

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

23 ago 2024, 18:38 UTC

Principales Noticias

The U.S. Is Bringing Back Free Covid Tests This Fall -- Barrons.com

2 ago 2024, 21:29 UTC

Principales Noticias

The Score: CrowdStrike, Apple, Intel and More Stocks That Defined the Week -- WSJ

1 ago 2024, 10:30 UTC

Principales Noticias

Moderna Cuts Revenue Guidance Amid Steeper Competition -- Barrons.com

3 jul 2024, 14:18 UTC

Adquisiciones, fusiones, absorciones

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

30 may 2024, 19:45 UTC

Principales Noticias

Bird Flu Confirmed in Third Farmworker. It's the First Case With Respiratory Symptoms. -- Barrons.com

29 may 2024, 15:56 UTC

Ganancias
Adquisiciones, fusiones, absorciones

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

10 may 2024, 20:11 UTC

Ganancias

These Stocks Moved the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, Gen Digital, JFrog, SoundHound, and More -- Barrons.com

10 may 2024, 14:49 UTC

Ganancias
Acciones populares

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

2 may 2024, 13:46 UTC

Ganancias
Acciones populares

Stocks to Watch Thursday: Carvana, NIO, Qualcomm, Peloton -- WSJ

2 may 2024, 10:31 UTC

Ganancias

Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout? -- IBD

2 may 2024, 09:08 UTC

Acciones populares

Stocks to Watch Thursday: Shell, Novo Nordisk, Apple -- WSJ

28 feb 2024, 14:14 UTC

Ganancias

Novavax Stock Sinks as Revenue Misses Estimates in 'Transition Year' -- Barrons.com

22 feb 2024, 16:00 UTC

Principales Noticias

Moderna Is Pivoting From Covid and the Results Are on Their Way -- Heard on the Street -- WSJ

22 feb 2024, 12:40 UTC

Ganancias

Moderna Stock Jumps on Surprise Profit After Earnings Beat. What to Expect in 2024. -- Barrons.com

2 nov 2023, 16:53 UTC

Ganancias

Moderna Tumbles As Light Guidance And Steep Losses Overshadow Sales Beat -- IBD

2 nov 2023, 08:58 UTC

Ganancias

These Stocks Are Moving the Most Today: Qualcomm, PayPal, SolarEdge, Roku, DoorDash, E.l.f. Beauty, and More -- Barrons.com

31 oct 2023, 16:35 UTC

Principales Noticias
Ganancias

Nevermind Covid, Investors Want a Pfizer Obesity Pill -- Heard on the Street -- WSJ

17 oct 2023, 10:00 UTC

Principales Noticias

Pfizer Looks for a Covid Bottom -- Heard on the Street -- WSJ

26 sept 2023, 09:30 UTC

Principales Noticias

The Big Pharma Stock Trade: Weight Loss Is In, Covid-19 Is Out -- WSJ

Comparación entre iguales

Cambio de precio

Moderna Inc Esperado

Precio Objetivo

By TipRanks

54.51% repunte

Estimación a 12 meses

Media 105.5 USD  54.51%

Máximo 238 USD

Mínimo 46 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Moderna Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

7

Comprar

9

Mantener

2

Vender

Puntuación técnica

By Trading Central

64.1101 / 73.44Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

284 / 365 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Moderna Inc

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.